Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TRDA Entrada Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TRDA
Price (delayed)
$7.93
Market cap
$300.97M
P/E Ratio
9.79
Dividend/share
N/A
EPS
$0.81
Enterprise value
$286.18M
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody,
Highlights
TRDA's quick ratio has surged by 95% since the previous quarter
TRDA's debt is down by 14% YoY and by 3.7% from the previous quarter
TRDA's net income has shrunk by 62% QoQ but it is up by 6% YoY
The equity has soared by 55% YoY but it has contracted by 2.7% from the previous quarter
TRDA's P/E is 11% more than its last 4 quarters average of 8.8
Key stats
What are the main financial stats of TRDA
Market
Valuations
Earnings
Shares outstanding
37.95M
Market cap
$300.97M
Enterprise value
$286.18M
Price to earnings (P/E)
9.79
Price to book (P/B)
0.71
Price to sales (P/S)
1.89
EV/EBIT
12.02
EV/EBITDA
10.37
EV/Sales
1.66
Revenue
$172.22M
Gross profit
$172.22M
Operating income
$4.11M
Net income
$24.78M
EBIT
$23.81M
EBITDA
$27.59M
Free cash flow
-$58.01M
Per share
Balance sheet
Liquidity
EPS
$0.81
EPS diluted
$0.74
Free cash flow per share
-$1.41
Book value per share
$11.1
Revenue per share
$4.19
TBVPS
$11.84
Total assets
$486.48M
Total liabilities
$69.22M
Debt
$57M
Equity
$417.26M
Working capital
$384.76M
Debt to equity
0.14
Current ratio
21.88
Quick ratio
21.08
Net debt/EBITDA
-0.54
Margins
Efficiency
Dividend
EBITDA margin
16%
Gross margin
100%
Net margin
14.4%
Operating margin
2.4%
Return on assets
4.6%
Return on equity
5.8%
Return on invested capital
5.5%
Return on capital employed
5.1%
Return on sales
13.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRDA stock price
How has the Entrada Therapeutics stock price performed over time
Intraday
-3.76%
1 week
2.06%
1 month
-14.08%
1 year
-48.17%
YTD
-54.14%
QTD
-12.28%
Financial performance
How have Entrada Therapeutics's revenue and profit performed over time
Revenue
$172.22M
Gross profit
$172.22M
Operating income
$4.11M
Net income
$24.78M
Gross margin
100%
Net margin
14.4%
The operating income has dropped by 91% since the previous quarter and by 83% year-on-year
Entrada Therapeutics's operating margin has shrunk by 89% QoQ and by 84% YoY
TRDA's net income has shrunk by 62% QoQ but it is up by 6% YoY
TRDA's net margin has plunged by 54% from the previous quarter
Price vs fundamentals
How does TRDA's price correlate with its fundamentals
Growth
What is Entrada Therapeutics's growth rate over time
Valuation
What is Entrada Therapeutics stock price valuation
P/E
9.79
P/B
0.71
P/S
1.89
EV/EBIT
12.02
EV/EBITDA
10.37
EV/Sales
1.66
TRDA's EPS has plunged by 54% from the previous quarter but it is up by 16% YoY
TRDA's P/E is 11% more than its last 4 quarters average of 8.8
The equity has soared by 55% YoY but it has contracted by 2.7% from the previous quarter
TRDA's price to book (P/B) is 41% lower than its last 4 quarters average of 1.2
The stock's P/S is 27% less than its last 4 quarters average of 2.6
Entrada Therapeutics's revenue has decreased by 18% from the previous quarter but it has increased by 6% YoY
Efficiency
How efficient is Entrada Therapeutics business performance
The ROIC has dropped by 67% since the previous quarter and by 55% year-on-year
Entrada Therapeutics's return on equity has shrunk by 66% QoQ and by 40% YoY
Entrada Therapeutics's return on assets has shrunk by 62% QoQ and by 4.2% YoY
TRDA's ROS has plunged by 56% from the previous quarter and by 45% YoY
Dividends
What is TRDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRDA.
Financial health
How did Entrada Therapeutics financials performed over time
Entrada Therapeutics's current ratio has surged by 96% QoQ
TRDA's quick ratio has surged by 95% since the previous quarter
TRDA's debt is 86% less than its equity
The equity has soared by 55% YoY but it has contracted by 2.7% from the previous quarter
Entrada Therapeutics's debt to equity has decreased by 44% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.